Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio’s (IBRX) Commercial Strategy?

ImmunityBio has now commercially launched its immunotherapy ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications, with distribution supported by regional …